BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 37278298)

  • 1. Targeting CDK4/6 in glioblastoma
    Zhang X; Ning L; Wu H; Yang S; Hu Z; Wang W; Cao Y; Xin H; You C; Lin F
    Nanoscale; 2023 Aug; 15(30):12518-12529. PubMed ID: 37278298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy.
    Yin L; Li H; Liu W; Yao Z; Cheng Z; Zhang H; Zou H
    Eur J Med Chem; 2018 Jan; 144():1-28. PubMed ID: 29247857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-resection treatment of glioblastoma with an injectable nanomedicine-loaded photopolymerizable hydrogel induces long-term survival.
    Zhao M; Danhier F; Bastiancich C; Joudiou N; Ganipineni LP; Tsakiris N; Gallez B; Rieux AD; Jankovski A; Bianco J; Préat V
    Int J Pharm; 2018 Sep; 548(1):522-529. PubMed ID: 30017818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomimetic Dp44mT-nanoparticles selectively induce apoptosis in Cu-loaded glioblastoma resulting in potent growth inhibition.
    Ismail M; Yang W; Li Y; Wang Y; He W; Wang J; Muhammad P; Chaston TB; Rehman FU; Zheng M; Lovejoy DB; Shi B
    Biomaterials; 2022 Oct; 289():121760. PubMed ID: 36044788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced targeting of invasive glioblastoma cells by peptide-functionalized gold nanorods in hydrogel-based 3D cultures.
    Gonçalves DPN; Rodriguez RD; Kurth T; Bray LJ; Binner M; Jungnickel C; Gür FN; Poser SW; Schmidt TL; Zahn DRT; Androutsellis-Theotokis A; Schlierf M; Werner C
    Acta Biomater; 2017 Aug; 58():12-25. PubMed ID: 28576716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A biocompatible and pH-responsive nanohydrogel based on cellulose nanocrystal for enhanced toxic reactive oxygen species generation.
    You C; Ning L; Wu H; Huang C; Wang F
    Carbohydr Polym; 2021 Apr; 258():117685. PubMed ID: 33593558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
    Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
    J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms.
    Olmez I; Brenneman B; Xiao A; Serbulea V; Benamar M; Zhang Y; Manigat L; Abbas T; Lee J; Nakano I; Godlewski J; Bronisz A; Abounader R; Leitinger N; Purow B
    Clin Cancer Res; 2017 Nov; 23(22):6958-6968. PubMed ID: 28814434
    [No Abstract]   [Full Text] [Related]  

  • 9. Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma.
    Olmez I; Zhang Y; Manigat L; Benamar M; Brenneman B; Nakano I; Godlewski J; Bronisz A; Lee J; Abbas T; Abounader R; Purow B
    Cancer Res; 2018 Aug; 78(15):4360-4369. PubMed ID: 29844123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellulose Nanocrystals-Incorporated Thermosensitive Hydrogel for Controlled Release, 3D Printing, and Breast Cancer Treatment Applications.
    Phan VHG; Murugesan M; Huong H; Le TT; Phan TH; Manivasagan P; Mathiyalagan R; Jang ES; Yang DC; Li Y; Thambi T
    ACS Appl Mater Interfaces; 2022 Sep; 14(38):42812-42826. PubMed ID: 36112403
    [No Abstract]   [Full Text] [Related]  

  • 11. A Preclinical Investigation of GBM-N019 as a Potential Inhibitor of Glioblastoma via Exosomal mTOR/CDK6/STAT3 Signaling.
    Wu ATH; Huang HS; Wen YT; Lawal B; Mokgautsi N; Huynh TT; Hsiao M; Wei L
    Cells; 2021 Sep; 10(9):. PubMed ID: 34572040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydrogel matrix presence and composition influence drug responses of encapsulated glioblastoma spheroids.
    Hill L; Bruns J; Zustiak SP
    Acta Biomater; 2021 Sep; 132():437-447. PubMed ID: 34010694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinacrine Mediated Sensitization of Glioblastoma (GBM) Cells to TRAIL through MMP-Sensitive PEG Hydrogel Carriers.
    Erkoc P; Cingöz A; Onder TB; Kizilel S
    Macromol Biosci; 2017 Feb; 17(2):. PubMed ID: 27762493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 3D bioprinted hydrogel mesh loaded with all-trans retinoic acid for treatment of glioblastoma.
    Mirani B; Pagan E; Shojaei S; Duchscherer J; Toyota BD; Ghavami S; Akbari M
    Eur J Pharmacol; 2019 Jul; 854():201-212. PubMed ID: 30974104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting PDGFRα-activated glioblastoma through specific inhibition of SHP-2-mediated signaling.
    Sang Y; Hou Y; Cheng R; Zheng L; Alvarez AA; Hu B; Cheng SY; Zhang W; Li Y; Feng H
    Neuro Oncol; 2019 Nov; 21(11):1423-1435. PubMed ID: 31232447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomimetic Nanosonosensitizers Combined with Noninvasive Ultrasound Actuation to Reverse Drug Resistance and Sonodynamic-Enhanced Chemotherapy against Orthotopic Glioblastoma.
    Chen H; Zhang S; Fang Q; He H; Ren J; Sun D; Lai J; Ma A; Chen Z; Liu L; Liang R; Cai L
    ACS Nano; 2023 Jan; 17(1):421-436. PubMed ID: 36573683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Injectable Thermo-Sensitive Chitosan Hydrogel Containing CPT-11-Loaded EGFR-Targeted Graphene Oxide and SLP2 shRNA for Localized Drug/Gene Delivery in Glioblastoma Therapy.
    Lu YJ; Lan YH; Chuang CC; Lu WT; Chan LY; Hsu PW; Chen JP
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32993166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temozolomide-loaded photopolymerizable PEG-DMA-based hydrogel for the treatment of glioblastoma.
    Fourniols T; Randolph LD; Staub A; Vanvarenberg K; Leprince JG; Préat V; des Rieux A; Danhier F
    J Control Release; 2015 Jul; 210():95-104. PubMed ID: 25982679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted nano-delivery of chemotherapy via intranasal route suppresses in vivo glioblastoma growth and prolongs survival in the intracranial mouse model.
    Sandbhor P; Goda J; Mohanty B; Gera P; Yadav S; Chekuri G; Chaudhari P; Dutt S; Banerjee R
    Drug Deliv Transl Res; 2023 Feb; 13(2):608-626. PubMed ID: 36245060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma.
    Liu X; Chen X; Shi L; Shan Q; Cao Q; Yue C; Li H; Li S; Wang J; Gao S; Niu M; Yu R
    J Exp Clin Cancer Res; 2019 May; 38(1):219. PubMed ID: 31122294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.